Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 7, 2015; 21(41): 11621-11635
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11621
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11621
Table 1 Phase II studies on second-line therapy (Monotherapy) in metastatic gastric cancer
II line agent | Total/eval pts | Performance status, n | Doses(mg/m2) | TreatmentORR | MedianTTP (mo) | MedianPFS(mo) | MedianOS (mo) | Toxicity,grade3-4 (%) | Ref. |
Irinotecan | 37/35 | ECOG 0/1 - 3/34 | Iri - 125 d1 weekly × 4 wk, q42 | 20.0% | 2.6 | NR | 5.2 | A/L/N/T/N-E/D/FN/I - 56.8/45.9/67.6/8.1/ 18.9/18.9/16.2/8.1 | Chun et al[19], 2004 |
Irinotecan | 39/30 | ECOG 0/1/2 - 18/10/2 | Iri - 100 d1,d8,d15 q28 | 15.3% | 2.9 | NR | 8.8 | A/N/Leu/Ano/D/F/- 13/30/17/23/17/13 | Mochizuki et al[20], 2013 |
Paclitaxel | 36/36 | ECOG 0/1/2 - 7/20/9 | Ptx - 225 d1 q21 | 22.2% | 5.0 | NR | 8.0 | L/T - 17/17 | Cascinu et al[21], 1998 |
Paclitaxel | 38/25 | ECOG 0/1/2 - 12/15/11 | Ptx - 80 d1, 8, 15 q28 | 24.0% | 2.1 | NR | 5.0 | L/N/T/Nau/Ano/D/ Neu - 29/32/8/3/3/3/6 | Hironaka et al[22], 2006 |
Paclitaxel | 45/44 | ECOG 0/1/2 - 26/13/6 | Ptx - 80 d1, 8, 15 q28 | 16.0% | NR | 2.6 | 7.8 | A/N/L/D/N-E/As/Neu - 11/16/18/2/4/11/2 | Kodera et al[23], 2007 |
Docetaxel | 30/29 | KPS Median 70 (R 60-100%) | Dtx - 100 d1 q21 | 17.0% | NR | NR | 6.0 | A/L/N - 7/7/18 | Giuliani et al[24], 2003 |
Docetaxel | 154/86 | ECOG 0-1/2 - 130/24 | Dtx - 75 d1 q21 | 14.0% | 2.6 | NR | 7.2 | A/N/FN/As - 10.5/12.5/9.9/13.6 | 1Jo et al[25], 2007 |
Docetaxel | 49/49 | ECOG 0/1/2 - 9/36/4 | Dtx - 75 d1 q21 | 16.5% | 2.5 | NR | 8.3 | A/L/N/FN/B/As/D/Neu - 5.4/4.8/5.4/5.4/1.2/ 10.8/2.4/8.4 | Lee et al[26], 2008 |
Nab-Paclitaxel | 56/54 | ECOG 0/1 - 33/23 | Nab-Ptx 250 d1 q21 | 27.8% | NR | 2.9 | 9.2 | A/L/N/Ly/Neu - 7.3/20/49.1/10.9/23.6 | Sasaki et al[27], 2014 |
Pemetrexed | 34/30 | ECOG 0/1/2 - 7/20/7 | Pem - 500 d1 q 21 | 63.6% | NR | 2.3 | 6.4 | A/N/T/As - 2.9/2.9/2.9/5.8 | Zhang et al[28], 2015 |
Sunitinib | 78/69 | ECOG 0/1 - 26/52 | Sun - 50 mg/d × 4 wk, q42 | 2.6% | 2.3 | 2.3 | 6.8 | A/L/N/T/E/D/HFS/S - 16.7/11.5/29.4/34.6/ 3.8/2.6/6.4/1.3 | Bang et al[29], 2010 |
Everolimus | 54/53 | ECOG 0/1 - 32/21 | Ev - 10 mg/d d1-28 | 0% | NR | 2.7 | 10.1 | P (gr 1-2)/A/Ly/As/S/ Ano/HyG/HyP/HyN/ - 15.1, 9.4/7.5/5.7/ 5.7/ 5.7/3.8/3.8/9.6 | Doi et al[30], 2010 |
- Citation: Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015; 21(41): 11621-11635
- URL: https://www.wjgnet.com/1007-9327/full/v21/i41/11621.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i41.11621